A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma [published correction appears in N Engl J Med. 2018;379:2185], N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Ribas, 2018, Cancer immunotherapy using checkpoint blockade, Science, 359, 1350, 10.1126/science.aar4060 Postow, 2018, Adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 1165, 10.1056/NEJMra1703481 Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 158, 10.1056/NEJMra1703481 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [published correction appears in Lancet. 2017;389:e5], Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (Poplar): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Mandal, 2019, Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response, Science, 364, 485, 10.1126/science.aau0447 Schumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 Verdegaal, 2016, Neoantigen landscape dynamics during human melanoma-T cell interactions, Nature, 536, 91, 10.1038/nature18945 Goodman, 2017, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol Cancer Ther, 16, 2598, 10.1158/1535-7163.MCT-17-0386 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, 51, 202, 10.1038/s41588-018-0312-8 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498 Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [published correction appears in Lancet. 2017;390:848], Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Hugo, 2016, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma, Cell, 165, 35, 10.1016/j.cell.2016.02.065 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data [published correction appears in Cancer Discov. 2012;2:960], Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 Zehir, 2017, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [published correction appears in Nat Med. 2017;23:1004], Nat Med, 23, 703, 10.1038/nm.4333 Cheng, 2015, Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology, J Mol Diagn, 17, 251, 10.1016/j.jmoldx.2014.12.006 Hellmann, 2018, Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer, Cancer Cell, 33, 843, 10.1016/j.ccell.2018.03.018 Rizvi, 2018, J Clin Oncol, 36, 633, 10.1200/JCO.2017.75.3384 Hoadley, 2018, Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer, Cell, 173, 291, 10.1016/j.cell.2018.03.022 Newman, 2015, Robust enumeration of cell subsets from tissue expression profiles, Nat Methods, 12, 453, 10.1038/nmeth.3337 Xu, 2018, TIP: a web server for resolving tumor immunophenotype profiling, Cancer Res, 78, 6575, 10.1158/0008-5472.CAN-18-0689 Zhang, 2019, Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy, Cancer Res, 79, 3940, 10.1158/0008-5472.CAN-19-0761 Ghosh, 2018, PARP1 depletion induces RIG-I-dependent signaling in human cancer cells, PLoS One, 13, 10.1371/journal.pone.0194611 Hsiehchen, 2020, DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden, Cell Rep Med, 1, 100034, 10.1016/j.xcrm.2020.100034 Diaz, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 373, 1979, 10.1056/NEJMc1510353 Wang, 2019, Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types, JAMA Oncol, 5, 1504, 10.1001/jamaoncol.2019.2963